BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18084326)

  • 21. Oncogenic fusion protein EWS/FLI1 down-regulates gene expression by both transcriptional and posttranscriptional mechanisms.
    France KA; Anderson JL; Park A; Denny CT
    J Biol Chem; 2011 Jul; 286(26):22750-7. PubMed ID: 21531709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors.
    Hu-Lieskovan S; Zhang J; Wu L; Shimada H; Schofield DE; Triche TJ
    Cancer Res; 2005 Jun; 65(11):4633-44. PubMed ID: 15930281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
    Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
    Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
    Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
    Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription.
    Navarro D; Agra N; Pestaña A; Alonso J; González-Sancho JM
    Carcinogenesis; 2010 Mar; 31(3):394-401. PubMed ID: 20019092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
    Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes.
    Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T
    Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1.
    Arvand A; Welford SM; Teitell MA; Denny CT
    Cancer Res; 2001 Jul; 61(13):5311-7. PubMed ID: 11431376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
    Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
    Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.
    Riggi N; Knoechel B; Gillespie SM; Rheinbay E; Boulay G; Suvà ML; Rossetti NE; Boonseng WE; Oksuz O; Cook EB; Formey A; Patel A; Gymrek M; Thapar V; Deshpande V; Ting DT; Hornicek FJ; Nielsen GP; Stamenkovic I; Aryee MJ; Bernstein BE; Rivera MN
    Cancer Cell; 2014 Nov; 26(5):668-681. PubMed ID: 25453903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells.
    Nozawa S; Ohno T; Banno Y; Dohjima T; Wakahara K; Fan DG; Shimizu K
    J Biol Chem; 2005 Jul; 280(30):27544-51. PubMed ID: 15919668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors.
    Matsunobu T; Tanaka K; Nakamura T; Nakatani F; Sakimura R; Hanada M; Li X; Okada T; Oda Y; Tsuneyoshi M; Iwamoto Y
    Cancer Res; 2006 Jan; 66(2):803-11. PubMed ID: 16424012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
    Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
    Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ewing's tumours, genetic and cellular aspects].
    Delattre O
    Pathol Biol (Paris); 2008 Jul; 56(5):257-9. PubMed ID: 18485618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
    Tanaka K; Iwakuma T; Harimaya K; Sato H; Iwamoto Y
    J Clin Invest; 1997 Jan; 99(2):239-47. PubMed ID: 9005992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
    Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H
    J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.
    Shi X; Zheng Y; Jiang L; Zhou B; Yang W; Li L; Ding L; Huang M; Gery S; Lin DC; Koeffler HP
    Nucleic Acids Res; 2020 Nov; 48(20):11434-11451. PubMed ID: 33080033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma.
    Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K
    Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.
    Erkizan HV; Uversky VN; Toretsky JA
    Clin Cancer Res; 2010 Aug; 16(16):4077-83. PubMed ID: 20547696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.